HEALTHSTORY 816· JUNE 26, 2026

One Patient Has Been Granted Exclusive Access to Eli Lilly's Obesity Drug Retatrutide Through FDA Compassionate Use

The Food and Drug Administration and Eli Lilly have permitted a single individual to receive retatrutide — Lilly's highly anticipated obesity drug candidate — through the FDA's compassionate use program, according to a scoop by STAT News…

NDNewsDialy Desk2 MIN READLLY

SOURCE

statnews.com

← PREVIOUS STORY 815SpaceX Stock Slides 14%, on Pace for Third Straight Day of Losses as Post-IPO Rally Fades NEXT STORY 817 →Airwallex Raises $320 Million at $11 Billion Valuation to Build Financial Infrastructure for AI Agents

Keep reading

More from the desk.

28HEALTH

Spruce Biosciences taps Adrian Quartel for chief medical officer role

A chief medical officer is the executive who decides how a drug company designs its clinical trials, interprets the data that comes back, and makes the medical case to regulators. Spruce Biosciences has filled that seat, hiring Adrian…

health1 MIN

39HEALTH

Federal health officials open a 30-day window to reconsider how children's vaccine recommendations are categorized

The federal government has taken a formal step toward reconsidering how children's vaccines are recommended in the United States, though no existing recommendations have changed. That step is a request for information

health2 MIN

53HEALTH

FDA clears Ultragenyx gene therapy in a week of back-to-back regulatory action

A gene therapy has received clearance for use in American patients, one of at least two approvals the Food and Drug Administration processed in a short stretch this week. Gene therapy, in p

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk